临床重症与药学超说明书用药专家共识(2021新增版)

2021-09-27 广东省药学会 广东省药学会官网

在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。

中文标题:

临床重症与药学超说明书用药专家共识(2021新增版)

发布机构:

广东省药学会

发布日期:

2021-09-27

简要介绍:

广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。

相关资料下载:
[AttachmentFileName(sort=1, fileName=临床重症与药学超说明书用药专家共识(2021新增版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=aba681c002205001, title=临床重症与药学超说明书用药专家共识(2021新增版), enTitle=, guiderFrom=广东省药学会官网, authorId=0, author=, summary=在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。, cover=https://img.medsci.cn/20211014/1634220187855_1608702.jpg, journalId=0, articlesId=null, associationId=1082, associationName=广东省药学会, associationIntro=广东省药学会前身为1945年成立的广州药师公会,1951年成为中国药学会广州分会。1958年在原有基础上扩大组织,成立中国药学会广东分会,负责组织全省药学科技工作者的相关活动。1985年起,中国药学会广东分会一直挂靠在广东省食品药品监督管理局(省医药管理局)。1991年,按民政部门文件要求更名为广东省药学会。, copyright=0, guiderPublishedTime=Mon Sep 27 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">广东省药学会重症医学用药专家委员会在</span><span style="color: #373737;">2020</span><span style="color: #373737;">年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。</span></p>, tagList=[TagDto(tagId=27238, tagName=超说明书用药)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=27238, guiderKeyword=超说明书用药, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3787, appHits=117, showAppHits=0, pcHits=1701, showPcHits=3669, likes=0, shares=11, comments=9, approvalStatus=1, publishedTime=Thu Oct 14 22:21:31 CST 2021, publishedTimeString=2021-09-27, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Thu Oct 14 22:07:37 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 09:31:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=临床重症与药学超说明书用药专家共识(2021新增版).pdf)])
临床重症与药学超说明书用药专家共识(2021新增版).pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207127, encodeId=a2a2120e1278f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:43:29 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192571, encodeId=0de611925e1ba, content=非常感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:21 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192570, encodeId=e3d711925e002, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:14 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192569, encodeId=a68f11925697f, content=广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:08 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076791, encodeId=9de610e679107, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Sat Dec 04 11:18:38 CST 2021, time=2021-12-04, status=1, ipAttribution=)]
    2022-03-30 洁巴子

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207127, encodeId=a2a2120e1278f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:43:29 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192571, encodeId=0de611925e1ba, content=非常感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:21 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192570, encodeId=e3d711925e002, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:14 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192569, encodeId=a68f11925697f, content=广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:08 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076791, encodeId=9de610e679107, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Sat Dec 04 11:18:38 CST 2021, time=2021-12-04, status=1, ipAttribution=)]
    2022-02-12 一己怀

    非常感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207127, encodeId=a2a2120e1278f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:43:29 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192571, encodeId=0de611925e1ba, content=非常感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:21 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192570, encodeId=e3d711925e002, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:14 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192569, encodeId=a68f11925697f, content=广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:08 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076791, encodeId=9de610e679107, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Sat Dec 04 11:18:38 CST 2021, time=2021-12-04, status=1, ipAttribution=)]
    2022-02-12 一己怀

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207127, encodeId=a2a2120e1278f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:43:29 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192571, encodeId=0de611925e1ba, content=非常感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:21 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192570, encodeId=e3d711925e002, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:14 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192569, encodeId=a68f11925697f, content=广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:08 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076791, encodeId=9de610e679107, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Sat Dec 04 11:18:38 CST 2021, time=2021-12-04, status=1, ipAttribution=)]
    2022-02-12 一己怀

    广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207127, encodeId=a2a2120e1278f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:43:29 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192571, encodeId=0de611925e1ba, content=非常感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:21 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192570, encodeId=e3d711925e002, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:14 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192569, encodeId=a68f11925697f, content=广东省药学会重症医学用药专家委员会在2020年发布了第一版《临床重症与药学超说明书用药专家共识》,总结了常用且有参考价值的临床重症药物超说明书使用循证医学证据。在本次专家共识更新中,新增了常用的镇痛镇静药物、多黏菌素、利奈唑胺、抗凝血用枸橼酸钠溶液、重组人血小板生成素在重症患者中的超说明书使用循证医学证据。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Feb 12 01:22:08 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076791, encodeId=9de610e679107, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Sat Dec 04 11:18:38 CST 2021, time=2021-12-04, status=1, ipAttribution=)]
    2021-12-04 yike168

    很好

    0